What changed: Neuroendocrine tumours
Every dated change on the records linked to Neuroendocrine tumours, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
2026 · 3
- 2026ApprovalLutetium-177 dotatate (radioligand equivalent)Lutetium-177 dotatate (radioligand equivalent) approved in US
Somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs), including foregut, midgut and hindgut tumours, in adults
- 2026GuidelineNeuroendocrine tumoursGuideline NCCN 2026 / ENETS 2023: Diagnosis and staging
Histology with Ki-67 grading; 68Ga/64Cu-DOTATATE PET/CT ± FDG PET; triple-phase CT or MRI of the liver; chromogranin A and syndrome-specific hormones; germline testing for pancreatic NETs and paragangliomas. (NCCN Neuroendocrine and Adrenal Tumors)
- 2026Milestone177Lu-edotreotideFDA accepts 177Lu-edotreotide NDA (PDUFA 28 August); ACTION-1 dosimetry published; pancreatic subgroup of COMPETE at ENETS
A milestone in how this cancer is treated.
2025 · 4
- 2025ApprovalCabozantinibCabozantinib approved in US
Advanced pancreatic and extra-pancreatic neuroendocrine tumours after prior therapy (CABINET)
- 2025Trial resultALPHAMEDIX-02ALPHAMEDIX-02 reported
ORR 54.
- 2025Trial resultCOMPETECOMPETE reported
PFS 23.
- 2025MilestoneCabozantinibCabozantinib approved (March); COMPETE positive (ENETS, Lancet); AlphaMedix phase 2 meets all endpoints (October)
A milestone in how this cancer is treated.
2024 · 3
- 2024Trial resultCABINET (Alliance A021602)CABINET (Alliance A021602) reported
PFS HR 0.
- 2024MilestoneNeuroendocrine tumoursNETTER-2: first-line PRRT
A milestone in how this cancer is treated.
- 2024MilestoneLutetium-177 dotatateNETTER-2: PRRT first line in grade 2-3; CABINET published; AlphaMedix Breakthrough designation
A milestone in how this cancer is treated.
2020 · 2
2019 · 1
2018 · 3
- 2018ApprovalIobenguane I-131 (therapeutic)Iobenguane I-131 (therapeutic) approved in US
Iobenguane scan-positive unresectable, locally advanced or metastatic phaeochromocytoma or paraganglioma in patients 12 and older (discontinued 2024)
- 2018MilestoneLutetium-177 dotatateLutathera approved
A milestone in how this cancer is treated.
- 2018MilestoneLutetium-177 dotatateLutathera approved (NETTER-1): PRRT enters standard care
A milestone in how this cancer is treated.
2017 · 1
2016 · 3
- 2016ApprovalGallium-68 DOTATATE (and Cu-64 DOTATATE)Gallium-68 DOTATATE (and Cu-64 DOTATATE) approved in US
PET localisation of SSTR-positive neuroendocrine tumours (Ga-68 DOTATATE)
- 2016ApprovalGallium-68 edotreotide (DOTATOC)Gallium-68 edotreotide (DOTATOC) approved in EU
PET localisation of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (as SomaKit TOC)
- 2016MilestoneSomatostatin receptor PET (68Ga/64Cu-DOTATATE)68Ga-DOTATATE PET (Netspot) approved; RADIANT-4 extends everolimus to lung/GI NETs
A milestone in how this cancer is treated.
2014 · 1
2011 · 2
2009 · 1
2000 · 1
1994 · 2
- 1994ApprovalIndium-111 pentetreotideIndium-111 pentetreotide approved in US
Scintigraphic localisation of primary and metastatic neuroendocrine tumours bearing somatostatin receptors
- 1994MilestoneSomatostatin receptor PET (68Ga/64Cu-DOTATATE)111In-octreotide scintigraphy (OctreoScan) approved
First SSTR imaging; later replaced by PET.